Shots:

• The P-III 1489 study has assessed Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in ratio (1:1) to treat HIV-1 infection in adults for 96 weeks- testing safety and efficacy
• P-III 1489 study results ((abacavir/dolutegravir/lamivudine (600/50/300mg- ABC/DTG/3TC) or Biktarvy): meGFR @96wks. (-7.8 mL/min vs. -9.6 mL/min); mean percent changes from baseline in spine and hip bone mineral density (spine: -0.71 vs. -0.22) (hip: -1.13 vs. -1.26); was well tolerated
• Bictegravir is a fixed dose drug containing 50 mg bictegravir- 200 mg emtricitabine- and 25 mg tenofovir alafenamide currently evaluated for the treatment naïve HIV-1 infection in adults

Ref: Gilead | Image: Gilead